OXiGENE secures $40 million financing from Kingsbridge Capital
Under the terms of the agreement, OXiGENE will determine the exact timing and amount of any CEFF financings, subject to certain conditions. OXiGENE can access up to $40
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
Under the terms of the agreement Upperton will use rP-nano technology to generate nanoparticles from recombinant proteins expressed in Novozymes’s proprietary, yeast-based expression system. The agreement extends previous